Cost-ef­fec­tive­ness of Mer­ck’s po­ten­tial hy­per­ten­sion drug will hinge on long-term da­ta, ICER says

ICER has pub­lished a draft re­port on the po­ten­tial cost-ef­fec­tive­ness of Mer­ck’s so­tater­cept, a po­ten­tial first-in-class fu­sion pro­tein un­der US re­view as an add-on ther­a­py …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER